James Meehan
Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer
Meehan, James; Gray, Mark; Mart�nez-P�rez, Carlos; Kay, Charlene; Pang, Lisa Y.; Fraser, Jennifer A.; Poole, Amy V.; Kunkler, Ian H.; Langdon, Simon P.; Argyle, David; Turnbull, Arran K.
Authors
Mark Gray
Carlos Mart�nez-P�rez
Charlene Kay
Lisa Y. Pang
Jennifer A. Fraser
Dr Amy Poole A.Poole@napier.ac.uk
Associate Professor
Ian H. Kunkler
Simon P. Langdon
David Argyle
Arran K. Turnbull
Abstract
Radiotherapy remains an important treatment modality in nearly two thirds of all cancers, including the primary curative or palliative treatment of breast cancer. Unfortunately, largely due to tumor heterogeneity, tumor radiotherapy response rates can vary significantly, even between patients diagnosed with the same tumor type. Although in recent years significant technological advances have been made in the way radiation can be precisely delivered to tumors, it is proving more difficult to personalize radiotherapy
regimens based on cancer biology. Biomarkers that provide prognostic or predictive information regarding a tumor’s intrinsic radiosensitivity or its response to treatment could
prove valuable in helping to personalize radiation dosing, enabling clinicians to make decisions between different treatment options whilst avoiding radiation-induced toxicity in patients unlikely to gain therapeutic benefit. Studies have investigated numerous ways
in which both patient and tumor radiosensitivities can be assessed. Tumor molecular profiling has been used to develop radiosensitivity gene signatures, while the assessment of specific intracellular or secreted proteins, including circulating tumor cells, exosomes and DNA, has been performed to identify prognostic or predictive biomarkers of radiation response. Finally, the investigation of biomarkers related to radiation-induced toxicity could provide another means by which radiotherapy could become personalized. In this review, we discuss studies that have used these methods to identify or develop prognostic/predictive signatures of radiosensitivity, and how such assays could be used in the future as a means of providing personalized radiotherapy.
Citation
Meehan, J., Gray, M., Martínez-Pérez, C., Kay, C., Pang, L. Y., Fraser, J. A., Poole, A. V., Kunkler, I. H., Langdon, S. P., Argyle, D., & Turnbull, A. K. (2020). Precision Medicine and the Role of Biomarkers of Radiotherapy Response in Breast Cancer. Frontiers in Oncology, 10, https://doi.org/10.3389/fonc.2020.00628
Journal Article Type | Review |
---|---|
Acceptance Date | Apr 6, 2020 |
Online Publication Date | Apr 24, 2020 |
Publication Date | 2020-04 |
Deposit Date | Apr 24, 2020 |
Publicly Available Date | Apr 24, 2020 |
Publisher | Frontiers Media |
Peer Reviewed | Peer Reviewed |
Volume | 10 |
DOI | https://doi.org/10.3389/fonc.2020.00628 |
Keywords | biomarkers of radiosensitivity, breast cancer, precision medicine, molecular signatures of radiosensitivity, biomarkers of radiation-induced toxicity |
Public URL | http://researchrepository.napier.ac.uk/Output/2655384 |
Files
Precision Medicine And The Role Of Biomarkers Of Radiotherapy Response In Breast Cancer
(1.1 Mb)
PDF
Publisher Licence URL
http://creativecommons.org/licenses/by/4.0/
Copyright Statement
© 2020 Meehan, Gray, Martínez-Pérez, Kay, Pang, Fraser, Poole, Kunkler, Langdon, Argyle and Turnbull. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
You might also like
Using immersive tech to enrich healthcare education
(2022)
Digital Artefact
Preferential activation of HIF-2 adaptive mechanisms in neuronal-like cells in response to hypoxia
(2017)
Presentation / Conference Contribution
The expression of the chloride co-transporters NKCC1 and KCC2 is reversed in the penumbra following
(2017)
Presentation / Conference Contribution
Chloride co-transporters as possible therapeutic targets for stroke
(2016)
Journal Article